A systems biology approach for understanding granuloma formation and function in tuberculosis

Systems Biology of Tuberculosis

Volumn , Issue , 2013, Pages 127-155

  Fallahi Sichani, Mohammad ^a   Marino, Simeone ^b   Flynn, Joanne L ^c   Linderman, Jennifer J ^d   Kirschner, Denise E ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84924184136     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-4966-9_7     Document Type: Chapter

References (105)

1. Bhatt K, Hickman SP, Salgame P (2004) Cutting edge: a new approach to modeling early lung immunity in murine tuberculosis. J Immunol 172:2748-2751
2. Wolf AJ, Desvignes L, Linas B, Banaiee N, Tamura T et al (2008) Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J Exp Med 205:105-115
3. Lazarevic V, Nolt D, Flynn JL (2005) Long-term control of Mycobacterium tuberculosis infection is mediated by dynamic immune responses. J Immunol 175:1107-1117
4. Chackerian AA, Alt JM, Perera TV, Dascher CC, Behar SM (2002) Dissemination of Mycobacterium tuberculosis is in fl uenced by host factors and precedes the initiation of T-cell immunity. Infect Immun 70:4501-4509
5. Flynn JL, Klein E (2010) "Pulmonary tuberculosis in monkeys" in A color atlas of comparative pulmonary tuberculosis histopathology. In: Leong J, Dartois V, Dick T (eds) CRC, Boca Raton, pp 83-106
6. Flynn JL, Chan J, Lin PL (2011) Macrophages and control of granulomatous in fl ammation in tuberculosis. Mucosal Immunol 4:271-278
7. Lin PL, Rodgers M, Smith L, Bigbee M, Myers A et al (2009) Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect Immun 77:4631-4642
8. Geng E, Kreiswirth B, Burzynski J, Schluger NW (2005) Clinical and radiographic correlates of primary and reactivation tuberculosis: a molecular epidemiology study. JAMA 293:2740-2745
9. Volkman HE, Pozos TC, Zheng J, Davis JM, Rawls JF et al (2010) Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science 327:466-469
10. Lin PL, Flynn JL (2010) Understanding latent tuberculosis: a moving target. J Immunol 185:15-22
11. Cooper AM (2009) Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 27:393-422
12. Cooper AM, Dalton DK, Stewart TA, Grif fi n JP, Russell DG et al (1993) Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 178:2243-2247
13. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA et al (1993) An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178:2249-2254
14. Gallegos AM, van Heijst JW, Samstein M, Su X, Pamer EG et al (2011) A gamma interferon independent mechanism of CD4 T cell mediated control of M. tuberculosis infection in vivo. PLoS Pathog 7:e1002052
15. Torrado E, Cooper AM (2011) What do we really know about how CD4 T cells control mycobacterium tuberculosis? PLoS Pathog 7:e1002196
16. Lin PL, Myers A, Smith L, Bigbee C, Bigbee M et al (2010) Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model. Arthritis Rheum 62:340-350
17. Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K et al (1995) Tumor necrosis factoralpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2:561-572
18. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J et al (2001) Tuberculosis associated with in fl iximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098-1104
19. Maglione PJ, Chan J (2009) How B cells shape the immune response against mycobacterium tuberculosis. Eur J Immunol 39:676-686
20. Flynn JL, Tsenova L, Izzo A, Kaplan G (2008) "Experimental animal models of tuberculosis" in Handbook of tuberculosis: Immunology and cell biology, In: Kaufmann SHE, Britton WJ (eds). Wiley-VCH Vol. 2, pp 389-417
21. Scanga CA, Mohan VP, Joseph H, Yu K, Chan J et al (1999) Reactivation of latent tuberculosis: variations on the cornell murine model. Infect Immun 67:4531-4538
22. Pichugin AV, Yan BS, Sloutsky A, Kobzik L, Kramnik I (2009) Dominant role of the sst1 locus in pathogenesis of necrotizing lung granulomas during chronic tuberculosis infection and reactivation in genetically resistant hosts. Am J Pathol 174:2190-2201
23. Singhal A, Aliouat el M, Herve M, Mathys V, Kiass M et al (2011) Experimental tuberculosis in the wistar rat: a model for protective immunity and control of infection. PLoS One 6:e18632
24. Orme IM (2006) Preclinical testing of new vaccines for tuberculosis: a comprehensive review. Vaccine 24:2-19
25. Helke KL, Mankowski JL, Manabe YC (2006) Animal models of cavitation in pulmonary tuberculosis. Tuberculosis (Edinb) 86:337-348
26. Turner OC, Basaraba RJ, Orme IM (2003) Immunopathogenesis of pulmonary granulomas in the guinea pig after infection with mycobacterium tuberculosis. Infect Immun 71:864-871
27. Hoff DR, Ryan GJ, Driver ER, Ssemakulu CC, De Groote MA et al (2011) Location of intraand extracellular M. tuberculosis populations in lungs of mice and guinea pigs during disease progression and after drug treatment. PLoS One 6:e17550
28. Basaraba RJ (2008) Experimental tuberculosis: The role of comparative pathology in the discovery of improved tuberculosis treatment strategies. Tuberculosis (Edinb) 88(suppl 1): S35-S47
29. Subbian S, Tsenova L, O'Brien P, Yang G, Koo MS et al (2011) Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology. Am J Pathol 179:289-301
30. Via LE, Lin PL, Ray SM, Carrillo J, Allen SS et al (2008) Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun 76:2333-2340
31. Allison MJ, Zappasodi P, Lurie MB (1962) Host-parasite relationships in natively resistant and susceptible rabbits on quantitative inhalation of tubercle bacilli: their signi fi cance for the nature of genetic resistance. Am Rev Respir Dis 85:553-569
32. Dannenberg AM (1994) Rabbit model of tuberculosis. In: Bloom BR (ed) Tuberculosis: pathogenesis, protection, and control. American Society for Microbiology, Washington, DC, pp 149-156
33. Cosma CL, Swaim LE, Volkman H, Ramakrishnan L, Davis JM (2006) Zebra fi sh and frog models of mycobacterium marinum infection. Curr Protoc Microbiol Chapter 10:Unit 10B.2
34. Capuano SV 3rd, Croix DA, Pawar S, Zinovik A, Myers A et al (2003) Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect Immun 71:5831-5844
35. Lin PL, Rutledge T, Green AM, Bigbee M, Fuhrman C et al (2012) CD4 T cell depletion exacerbates acute Mycobacterium tuberculosis while reactivation of latent infection is dependent on severity of tissue depletion in cynomolgus macaques. AIDS Res Hum Retroviruses. (in press)
36. Mattila JT, Diedrich CR, Lin PL, Phuah J, Flynn JL (2011) Simian immunode fi ciency virusinduced changes in T cell cytokine responses in cynomolgus macaques with latent Mycobacterium tuberculosis infection are associated with timing of reactivation. J Immunol 186:3527-3537
37. Diedrich CR, Mattila JT, Klein E, Janssen C, Phuah J et al (2010) Reactivation of latent tuberculosis in cynomolgus macaques infected with SIV is associated with early peripheral T cell depletion and not virus load. PLoS One 5:e9611
38. Mehra S, Golden NA, Dutta NK, Midkiff CC, Alvarez X et al (2011) Reactivation of latent tuberculosis in rhesus macaques by coinfection with simian immunode fi ciency virus. J Med Primatol 40:233-243
39. Davis SL, Nuermberger EL, Um PK, Vidal C, Jedynak B et al (2009) Noninvasive pulmonary [18F]-2-fl uoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob Agents Chemother 53:4879-4884
40. Puissegur MP, Botanch C, Duteyrat JL, Delsol G, Caratero C et al (2004) An in vitro dual model of mycobacterial granulomas to investigate the molecular interactions between mycobacteria and human host cells. Cell Microbiol 6:423-433
41. Bowdish DM, Sakamoto K, Kim MJ, Kroos M, Mukhopadhyay S et al (2009) MARCO, TLR2, and CD14 are required for macrophage cytokine responses to mycobacterial trehalose dimycolate and mycobacterium tuberculosis. PLoS Pathog 5:e1000474
42. Fallahi-Sichani M, Schaller MA, Kirschner DE, Kunkel SL, Linderman JJ (2010) Identi fi cation of key processes that control tumor necrosis factor availability in a tuberculosis granuloma. PLoS Comput Biol 6:e1000778
43. Chensue SW, Warmington K, Ruth J, Lincoln P, Kuo MC et al (1994) Cytokine responses during mycobacterial and schistosomal antigen-induced pulmonary granuloma formation. production of Th1 and Th2 cytokines and relative contribution of tumor necrosis factor. Am J Pathol 145:1105-1113
44. Chensue SW, Kunkel SL (2003) Cytokines and chemokines in granulomatous in fl ammation. In: Boros DL (ed) Granulomatous infections and in fl ammations: cellular and molecular mechanisms. ASM Press, Washington, DC, pp 29-64.
45. Fallahi-Sichani M, El-Kebir M, Marino S, Kirschner DE, Linderman JJ (2011) Multiscale computational modeling reveals a critical role for TNF-a receptor 1 dynamics in tuberculosis granuloma formation. J Immunol 186:3472-3483
46. Ray JC, Flynn JL, Kirschner DE (2009) Synergy between individual TNF-dependent functions determines granuloma performance for controlling Mycobacterium tuberculosis infection. J Immunol 182:3706-3717
47. Segovia-Juarez JL, Ganguli S, Kirschner D (2004) Identifying control mechanisms of granuloma formation during M. tuberculosis infection using an agent-based model. J Theor Biol 231:357-376
48. Warrender C, Forrest S, Koster F (2006) Modeling intercellular interactions in early mycobacterium infection. Bull Math Biol 68:2233-2261
49. Bru A, Cardona PJ (2010) Mathematical modeling of tuberculosis bacillary counts and cellular populations in the organs of infected mice. PLoS One 5:e12985
50. Ganguli S, Gammack D, Kirschner DE (2005) A metapopulation model of granuloma formation in the lung during infection with mycobacterium tuberculosis. Math Biosci Eng 2:535-560
51. Gammack D, Doering CR, Kirschner DE (2004) Macrophage response to Mycobacterium tuberculosis infection. J Math Biol 48:218-242
52. Marino S, Sud D, Plessner H, Lin PL, Chan J et al (2007) Differences in reactivation of tuberculosis induced from anti-TNF treatments are based on bioavailability in granulomatous tissue. PLoS Comput Biol 3:1909-1924
53. Sud D, Bigbee C, Flynn JL, Kirschner DE (2006) Contribution of CD8+ T cells to control of Mycobacterium tuberculosis infection. J Immunol 176:4296-4314
54. Wigginton JE, Kirschner D (2001) A model to predict cell-mediated immune regulatory mechanisms during human infection with mycobacterium tuberculosis. J Immunol 166:1951-1967
55. Magombedze G, Garira W, Mwenje E (2006) Modelling the human immune response mechanisms to Mycobacterium tuberculosis infection in the lungs. Math Biosci Eng 3:661-682
56. Day J, Friedman A, Schlesinger LS (2009) Modeling the immune rheostat of macrophages in the lung in response to infection. Proc Natl Acad Sci USA 106:11246-11251
57. Marino S, El-Kebir M, Kirschner D (2011) A hybrid multi-compartment model of granuloma formation and T cell priming in tuberculosis. J Theor Biol 280:50-62
58. Marino S, Pawar S, Fuller CL, Reinhart TA, Flynn JL et al (2004) Dendritic cell traf fi cking and antigen presentation in the human immune response to mycobacterium tuberculosis. J Immunol 173:494-506
59. Marino S, Myers A, Flynn JL, Kirschner DE (2010) TNF and IL-10 are major factors in modulation of the phagocytic cell environment in lung and lymph node in tuberculosis: a next-generation two-compartmental model. J Theor Biol 265:586-598
60. Flynn JL (2004) Immunology of tuberculosis and implications in vaccine development. Tuberculosis (Edinb) 84:93-101
61. Marino S, Hogue IB, Ray CJ, Kirschner DE (2008) A methodology for performing global uncertainty and sensitivity analysis in systems biology. J Theor Biol 254:178-196
62. Algood HM, Lin PL, Flynn JL (2005) Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis 41(suppl 3):S189-S193
63. Algood HM, Lin PL, Yankura D, Jones A, Chan J et al (2004) TNF in fl uences chemokine expression of macrophages in vitro and that of CD11b+ cells in vivo during Mycobacterium tuberculosis infection. J Immunol 172:6846-6857
64. Algood HM, Chan J, Flynn JL (2003) Chemokines and tuberculosis. Cytokine Growth Factor Rev 14:467-477
65. Lin PL, Plessner HL, Voitenok NN, Flynn JL (2007) Tumor necrosis factor and tuberculosis. J Investig Dermatol Symp Proc 12:22-25
66. Chakravarty SD, Zhu G, Tsai MC, Mohan VP, Marino S et al (2008) Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous in fl ammation and disorganizes granulomas in the lungs. Infect Immun 76:916-926
67. Clay H, Volkman HE, Ramakrishnan L (2008) Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death. Immunity 29:283-294
68. Iliopoulos A, Psathakis K, Aslanidis S, Skagias L, S fi kakis PP (2006) Tuberculosis and granuloma formation in patients receiving anti-TNF therapy. Int J Tuberc Lung Dis 10:588-590
69. Chensue SW, Warmington KS, Ruth JH, Lincoln P, Kunkel SL (1995) Cytokine function during mycobacterial and schistosomal antigen-induced pulmonary granuloma formation. Local and regional participation of IFN-gamma, IL-10, and TNF. J Immunol 154:5969-5976
70. Schutze S, Machleidt T, Adam D, Schwandner R, Wiegmann K et al (1999) Inhibition of receptor internalization by monodansylcadaverine selectively blocks p55 tumor necrosis factor receptor death domain signaling. J Biol Chem 274:10203-10212
71. Schneider-Brachert W, Tchikov V, Neumeyer J, Jakob M, Winoto-Morbach S et al (2004) Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity 21:415-428
72. Schneider-Brachert W, Tchikov V, Merkel O, Jakob M, Hallas C et al (2006) Inhibition of TNF receptor 1 internalization by adenovirus 14.7K as a novel immune escape mechanism. J Clin Invest 116:2901-2913
73. Neumeyer J, Hallas C, Merkel O, Winoto-Morbach S, Jakob M et al (2006) TNF-receptor I defective in internalization allows for cell death through activation of neutral sphingomyelinase. Exp Cell Res 312:2142-2153
74. Harris J, Hope JC, Keane J (2008) Tumor necrosis factor blockers in fl uence macrophage responses to mycobacterium tuberculosis. J Infect Dis 198:1842-1850
75. Gutierrez MG, Mishra BB, Jordao L, Elliott E, Anes E et al (2008) NF-kappa B activation controls phagolysosome fusion-mediated killing of mycobacteria by macrophages. J Immunol 181:2651-2663
76. Keane J, Shurtleff B, Kornfeld H (2002) TNF-dependent BALB/c murine macrophage apoptosis following Mycobacterium tuberculosis infection inhibits bacillary growth in an IFNgamma independent manner. Tuberculosis (Edinb) 82:55-61
77. Keane J, Balcewicz-Sablinska MK, Remold HG, Chupp GL, Meek BB et al (1997) Infection by Mycobacterium tuberculosis promotes human alveolar macrophage apoptosis. Infect Immun 65:298-304
78. Zhou Z, Connell MC, MacEwan DJ (2007) TNFR1-induced NF-kappaB, but not ERK, p38MAPK or JNK activation, mediates TNF-induced ICAM-1 and VCAM-1 expression on endothelial cells. Cell Signal 19:1238-1248
79. Russell DG, Barry CE 3rd, Flynn JL (2010) Tuberculosis: what we don't know can, and does, hurt us. Science 328:852-856
80. Wallis RS, Broder M, Wong J, Lee A, Hoq L (2005) Reactivation of latent granulomatous infections by in fl iximab. Clin Infect Dis 41(suppl 3):S194-S198
81. Keane J (2005) TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford) 44:714-720
82. Winthrop KL (2006) Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2:602-610
83. Wallis RS (2008) Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 8:601-611
84. Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH (2003) Comparison of the ef fi cacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and in fl iximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 62(suppl 2):ii13-ii16
85. Gladman DD (2008) Adalimumab, etanercept and in fl iximab are equally effective treatments for patients with psoriatic arthritis. Nat Clin Pract Rheumatol 4:510-511
86. Wallis RS (2009) Infectious complications of tumor necrosis factor blockade. Curr Opin Infect Dis 22:403-409
87. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38:1261-1265
88. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P et al (2009) Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective french research axed on tolerance of biotherapies registry. Arthritis Rheum 60:1884-1894
89. Fonseca JE, Canhao H, Silva C, Miguel C, Mediavilla MJ et al (2006) Tuberculosis in rheumatic patients treated with tumour necrosis factor alpha antagonists: the portuguese experience. Acta Reumatol Port 31:247-253
90. Fallahi-Sichani M, Flynn JL, Linderman JJ, Kirschner DE (2012) Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability. J Immunol 188:3169-3178
91. Plessner HL, Lin PL, Kohno T, Louie JS, Kirschner D et al (2007) Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis 195:1643-1650
92. Cook DN, Bottomly K (2007) Innate immune control of pulmonary dendritic cell traf fi cking. Proc Am Thorac Soc 4:234-239
93. Randolph GJ, Angeli V, Swartz MA (2005) Dendritic-cell traf fi cking to lymph nodes through lymphatic vessels. Nat Rev Immunol 5:617-628
94. Celli S, Garcia Z, Bousso P (2005) CD4 T cells integrate signals delivered during successive DC encounters in vivo. J Exp Med 202:1271-1278
95. Celli S, Lemaitre F, Bousso P (2007) Real-time manipulation of T cell-dendritic cell interactions in vivo reveals the importance of prolonged contacts for CD4+ T cell activation. Immunity 27:625-634
96. Zheng H, Jin B, Henrickson SE, Perelson AS, von Andrian UH et al (2008) How antigen quantity and quality determine T-cell decisions in lymphoid tissue. Mol Cell Biol 28:4040-4051
97. Linderman JJ, Riggs T, Pande M, Miller M, Marino S et al (2010) Characterizing the dynamics of CD4+ T cell priming within a lymph node. J Immunol 184:2873-2885
98. Steinman RM (2001) Dendritic cells and the control of immunity: enhancing the ef fi ciency of antigen presentation. Mt Sinai J Med 68:160-166
99. Kirschner DE, Webb GF (1998) Immunotherapy of HIV-1 infection. J Biol Syst 6:71-83
100. Kirschner D, Panetta JC (1998) Modeling immunotherapy of the tumor-immune interaction. J Math Biol 37:235-252
101. Churchyard GJ, Kaplan G, Fallows D, Wallis RS, Onyebujoh P et al (2009) Advances in immunotherapy for tuberculosis treatment. Clin Chest Med 30:769-782, ix
102. Rook GA, Lowrie DB, Hernandez-Pando R (2007) Immunotherapeutics for tuberculosis in experimental animals: is there a common pathway activated by effective protocols? J Infect Dis 196:191-198
103. Wallis RS (2005) Reconsidering adjuvant immunotherapy for tuberculosis. Clin Infect Dis 41:201-208
104. Kim MS, Lee SH, Song MY, Yoo TH, Lee BK et al (2007) Comparative analyses of complex formation and binding sites between human tumor necrosis factor-alpha and its three antagonists elucidate their different neutralizing mechanisms. J Mol Biol 374:1374-1388
105. Nestorov I (2005) Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum 34:12-18